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Table 1
* Total
N 222
Age 58 (20-72)
HCT-SCI 0-1/2/>3 53/54/90
PS 90-100/70-80/50-60 107/108/7
AML/ALL/MDS/NHL and HD/MM/others 76/10/22/71/35/8
Disease Risk index
Low/Int/High/VHigh
26/132/58/6 12%/59%/26%/3%
MRD/MUD/ MMUD 111/77/34 50%/35%/15%
* HCT-SCI indicates: hematopoietic cell transplantation speciﬁc comor-
bidity index; MRD, Matched related donor; MUD, Matched unrelated donor;
MMUD, Mismatched unrelated donor
Table 2
n 2-y OS 2-y PFS 2-y RR 2-y NRM
All patients 222 64% 54% 28% 20%
Low DRI 26 (12% 92% 69% 8% 13%
Int DRI 132 (59%) 69% 56% 27% 21%
High/VHigh DRI 64 (29%) 43% 40% 38% 31%
> 58 years 120 61% 50% / 27%
< 58 years 102 67% 60% / 16%
MRD 111 67% 53% / 16%
MUD+ MMUD 111 60% 55% / 28%
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Innate and therapy-induced states of immunosuppres-
sion are associated with a variety of potentially infectious
idiopathic clinical syndromes. Using unbiased, next-genera-
tion sequencing, we investigated the metagenome of cord
colitis syndrome (CCS), a recently described transplantation-
associated colitis syndrome, in order to identify a candidate
infectious trigger. Shotgunwhole genome sequencing of DNA
was performed followed by computational classiﬁcation of
reads. A large proportion of reads remained unmapped,
suggesting the presence of a potentially novel organism. In
order to investigate the source of these unmapped reads, de
novo computational assembly of nonhuman reads was per-
formed and yielded 98 contigs of > 2.5kb in length covering
a total of 7.65Mb. Read coverage and GC content was similar
for all of these contigs, suggesting they corresponded to
a common organism. Phylogenetic analysis of this draft
genome revealed that this organism was a novel species,
which we have provisionally named Bradyrhizobium enterica.
PCR conﬁrmed the presence of B. enterica in three additional
CCS patients and demonstrated absence of B. enterica in
normal colon, colon cancer and graft-versus-host disease
controls. In summary, we have demonstrated the assembly of
a novel bacterial draft genome from human tissue specimens
without isolation or culture of the organism. This organism,
provisionally named B. enterica, is associated with CCS sug-
gesting that it may function as an opportunistic human
pathogen.345
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Introduction: We have treated 222 consecutive patients
eligible for allo HSCT with the same RIC from June 2005 up to
March 2012.We particularly studied the impact of age, donor
source and of the recent disease risk index (DRI) published
by Amand et al (Blood 2012).
Patients and methods: All patients were treated for
hematologic malignancies and were prepared with Flu-
darabin (30 mg/m2/D x 5 D, IV Busulfan (3.2 mg/Kg/D x 2
D, and rabbit antithymocyte globulin (rATG) (2.5 mg/Kg/D
x 2 D). All patients received CSA from D-1 with the
addition of MMF in case of MMUD as post graft
immunosuppression.Results: As for August 2012, follow-up is 24 months (4-77).
Patients characteristics are presented in Table 1; median age
was 58 years with 45% and 30% of the patients presenting
with a HCT-SCI > 2 and a high or very high DRI
respectively. 50% of donors were related siblings. Analyses
of outcomes are presented in Table 2. Age only inﬂuenced
NRM (P ¼ .21). Donor origin has no inﬂuence on any
outcome variable. DRI inﬂuenced OS (P ¼ .000017) (Figure
1), PFS (P ¼ .00045) (Figure 2), relapse (P ¼ .0073) and at
a lesser degree NRM (P ¼ .056).
Conclusions: Overall results are promising. They validate the
previously published DRI and indicate populations where
efforts should be focused. Interestingly results are similar
whatever the donor is.346
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Purpose: Over the years, we have tuned the chemotherapy
dose intensity of a busulfan based RIC regimen with the aim
to better control disease while retaining a low toxicity
proﬁle. Here, we retrospectively analyzed a cohort of patients
with myeloid malignancies treated identically in two French
centers.
Patients and methods: From 2005 to 2010 in Marseille and
Nantes we transplanted 165 patients (median age: 56.8 years
